Stem Cell Therapies in Clinical Trials: Progress and Challenges

Abstract

Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variety of stem cell types. To date, there have been few reports of safety issues arising from autologous or allogeneic transplants. Many cells administered show transient presence for a few days with trophic influences on immune or inflammatory responses. Limbal stem cells have been registered as a product for eye burns in Europe and mesenchymal stem cells have been approved for pediatric graft versus host disease in Canada and New Zealand. Many other applications are progressing in trials, some with early benefits to patients.

Mesenchymal stem cell therapy for acute and chronic pancreatitis

“…Because MSCs do not have the major histocompatibility complex class II antigen, rejection does not occur, even after allogenic transplantation. The effect of MSC transplantation has been investigated in several gastrointestinal diseases in animal models [3][4][5] and in human trials [6].…”

Stem cells: from biomedical research towards clinical applications

“…Now, other stem cell types, such as mesenchymal stem cells, are rapidly moving into the clinic and also ES cell and iPS cell-derived cells are being tested in clinical trials [8,9].…”

Current mesenchymal stem cell applications with regard to clinical studies

“…Rejeneratif ve reperatif tıpta çeitli kök hücre tipleri kullanımı günümüzde klinik aratırmalara geni bir spektruma yayılmı durumdadır. [10,11] MezenK‹Mal KöK Hücreler ve Güncel UyGUlaMalar…”